Anixa is focused on the treatment and prevention of cancer.

Anixa Biosciences, Inc. is developing therapies and vaccines that are focused on critical unmet needs in oncology.  Anixa’s programs are using the body’s immune system to take multiple approaches in fighting cancer—CAR-T cell therapy to treat cancer and vaccines to prevent cancer.


Therapeutics

CAR-T

We are developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient’s own immune cells to fight cancer.

Vaccines

Breast Cancer Vaccine

We are developing a revolutionary vaccine technology focused on preventing breast cancer, specifically triple negative breast cancer, the most lethal form of the disease.

Ovarian Cancer Vaccine

Using a similar mechanism of action as our breast cancer vaccine technology, we are developing a vaccine to prevent the occurrence of ovarian cancer.

Lung, Colon, & Prostate Cancer Vaccines

We have commenced a cancer vaccine discovery program utilizing the same mechanism as our breast and ovarian cancer vaccines, to develop additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate.

Sign up for email Updates

Be The First to Receive Breaking News

Sign Up Now
Logo Itus

Latest News & Events

Anixa Biosciences Announces Japanese Patent on Breast Cancer Vaccine Technology

Read More...

Anixa Biosciences Announces $5 Million Share Repurchase Program

Read More...

Anixa Biosciences Treats Sixth Patient in its Ovarian Cancer CAR-T Clinical Trial

Read More...

Stock Data

View Investors Relations
Nasdaq: ANIX
Price
Change